Mogrify Appoints Dr Jonathan Appleby as Chief Scientific Officer
CAMBRIDGE, England & TOKYO--(BUSINESS WIRE)--Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), a leader in regenerative medicine, today announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.
CAMBRIDGE, England--(BUSINESS WIRE)--Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Dr. Louise Modis as Chief Scientific Officer, following the recent completion of a $33 million USD Series A funding. Louise is an accomplished scientific leader in therapeutic discovery and development, and holds considerable experience in the progression of pre-clinical and clinical-stage assets, across various modalities and therapeutic areas. In her new role, Louise will lead the advancement of the Company’s internal programs to help address high unmet clinical need in ophthalmology, immuno-oncology and other disease areas.
Mogrify Limited, a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, and the MRC Laboratory of Molecular Biology (LMB), a research laboratory dedicated to understanding important biological processes at the molecular level, has announced an exploratory research collaboration.
Mogrify Raises Additional $16 Million to Advance its Mission to Transform the Development of Life-saving Cell Therapies